ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.
A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer, has treated the first patient, according to... Read More
A type of mutation in a single nucleotide called rs11672691 plays a role in the development of aggressive prostate cancer by... Read More
Using artificial intelligence to identify genetic patterns in prostate cancer tissue could help shed light on how tumors develops and improve clinical... Read More
NucleoBio’s investigative therapy Prostreat was seen to be better at preventing the growth and spread of metastatic castration-resistant prostate cancer... Read More
IsoPSA, a blood test developed by Cleveland Diagnostics that detects cancer-derived PSA, is more accurate in diagnosing prostate cancer than a... Read More
An implanted medical device that attracts and kills cancer cells has received a European patent. The device was developed by... Read More
IsoRay is getting ready to release a new delivery system for real-time prostate cancer brachytherapy called Build-Blu, the company recently... Read More
The suicide rate in patients with urological cancers — such as prostate, kidney or bladder cancer — is five times... Read More
Using magnetic resonance imaging to identify possible prostate cancer tumors significantly reduces the need for invasive biopsies, a Phase 3... Read More
Do prostate cancer diagnoses undermine the health of patients’ partners? A team of Danish researchers says “yes.” Led by Jeanne... Read More
